Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors
2015; American Association for Cancer Research; Volume: 14; Issue: 12_Supplement_2 Linguagem: Inglês
10.1158/1535-7163.targ-15-b109
ISSN1538-8514
AutoresDavid M. Hyman, Lillian M. Smyth, Philippe L. Bédard, Amit M. Oza, Emma Dean, Anne Armstrong, João Paulo da Silveira Nogueira Lima, Hideaki Bando, Peter Kabos, José Alejandro Pérez Fidalgo, Kathleen N. Moore, Shannon N. Westin, Benoît You, Sarat Chandarlapaty, Leila Alland, Helen Ambrose, Andrew Foxley, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Shaista Salim, Gaia Schiavon, Kenji Tamura, José Baselga, Udai Banerji,
Tópico(s)RNA modifications and cancer
ResumoAbstract This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session: 10:00 AM ET Saturday, November 7. Citation Format: David M. Hyman, Lillian Smyth, Philippe L. Bedard, Amit Oza, Emma Dean, Anne Armstrong, Joao Lima, Hideaki Bando, Peter Kabos, J. Alejandro Perez-Fidalgo, Kathleen Moore, Shannon N. Westin, Benoit You, Sarat Chandarlapaty, Leila Alland, Helen Ambrose, Andrew Foxley, Justin Lindemann, Martin Pass, Paul Rugman, Shaista Salim, Gaia Schiavon, Kenji Tamura, Jose Baselga, Udai Banerji. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B109.
Referência(s)